Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFP464 +/- Faslodex in ER+ Breast Cancer
NCT01233947Phase 2Terminated
- Sponsor
- Tigris Pharmaceuticals, Inc.
- Start
- May 2011
- Primary completion
- Aug 2012
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of AFP-464 in breast cancer, sponsored by Tigris Pharmaceuticals, Inc.. Started May 2011; status: terminated.
02
Drugs
AFP-464
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01233947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01233947.